Daniel J Cushing

Summary

Publications

  1. doi PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects
    Daniel J Cushing
    Prism Pharmaceuticals Inc, King of Prussia, Pennsylvania, United States
    Eur J Pharmacol 607:167-72. 2009
  2. doi Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans
    Daniel J Cushing
    Prism Pharmaceuticals, King of Prussia, PA 19406, USA
    Clin Exp Pharmacol Physiol 39:3-8. 2012
  3. doi Bioequivalence of 2 intravenous amiodarone formulations in healthy participants
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, 1150 First Avenue, Suite 1050, King of Prussia, PA 19406, USA
    J Clin Pharmacol 49:407-15. 2009
  4. doi Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs
    Daniel J Cushing
    Prism Pharmaceuticals Inc, King of Prussia, PA 19406, USA
    Cardiovasc Toxicol 9:126-33. 2009
  5. doi The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, King of Prussia, Pennsylvania, USA
    Clin Exp Pharmacol Physiol 37:358-61. 2010
  6. doi Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans
    Daniel J Cushing
    Prism Pharmaceuticals, King of Prussia, Pennsylvania, USA
    Am J Cardiol 104:1152-7. 2009
  7. doi Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, King of Prussia, PA, USA
    Eur J Pharmacol 635:165-70. 2010
  8. doi PM101: intravenous amiodarone formulation changes can improve medication safety
    Paul F Souney
    Prism Pharmaceuticals, Inc, 1016 West Ninth Avenue, Suite 130, King of Prussia, PA 19406, USA
    Expert Opin Drug Saf 9:319-33. 2010

Detail Information

Publications8

  1. doi PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects
    Daniel J Cushing
    Prism Pharmaceuticals Inc, King of Prussia, Pennsylvania, United States
    Eur J Pharmacol 607:167-72. 2009
    ..This study provides a useful model for the continued search for a safe and effective intravenous amiodarone formulation devoid of the hypotensive risk associated with the current commercial formulation...
  2. doi Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans
    Daniel J Cushing
    Prism Pharmaceuticals, King of Prussia, PA 19406, USA
    Clin Exp Pharmacol Physiol 39:3-8. 2012
    ....
  3. doi Bioequivalence of 2 intravenous amiodarone formulations in healthy participants
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, 1150 First Avenue, Suite 1050, King of Prussia, PA 19406, USA
    J Clin Pharmacol 49:407-15. 2009
    ..Because the ratios and their CI fell between the limits of 0.8 and 1.25, bioequivalence of these 2 formulations was established. No safety concerns unique to PM101 were identified...
  4. doi Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs
    Daniel J Cushing
    Prism Pharmaceuticals Inc, King of Prussia, PA 19406, USA
    Cardiovasc Toxicol 9:126-33. 2009
    ..PM101 may represent a formulation of intravenous amiodarone that could be administered rapidly without dilution in the setting of life-threatening cardiac arrhythmias...
  5. doi The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, King of Prussia, Pennsylvania, USA
    Clin Exp Pharmacol Physiol 37:358-61. 2010
    ..5. These data suggest that consideration should be given to intravenous amiodarone as a potential cause for sustained hypotension during prolonged infusion...
  6. doi Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans
    Daniel J Cushing
    Prism Pharmaceuticals, King of Prussia, Pennsylvania, USA
    Am J Cardiol 104:1152-7. 2009
    ..The absence of a hypotensive effect of AIV in this population suggests that further evaluation is needed in a patient population with cardiac disease...
  7. doi Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, King of Prussia, PA, USA
    Eur J Pharmacol 635:165-70. 2010
    ..It's utility as a bolus injection as well as infusion, its rapid efficacy and its rapid clearance make this an ideal candidate for clinical development...
  8. doi PM101: intravenous amiodarone formulation changes can improve medication safety
    Paul F Souney
    Prism Pharmaceuticals, Inc, 1016 West Ninth Avenue, Suite 130, King of Prussia, PA 19406, USA
    Expert Opin Drug Saf 9:319-33. 2010
    ..PM101 has been developed to address several of these important issues. Take home message: PM101 is a new formulation of A-IV that is stable in commonly used infusion materials and avoids co-solvent related toxicities...